Stock Events

Stock Events

Neurotech International Limited 

A$0.013500
2
+A$0.00+3.85% Thursday 04:55

Statistics

Day High
0.014
Day Low
0.013
52W High
0.029
52W Low
0.01
Volume
2,570,802
Avg. Volume
2,313,048
Mkt Cap
17.79M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26AugExpected
Q2 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
-0.72
-0.48
-0.24
-0
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-10.6MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Anavex Life Sciences
AVXL
Mkt Cap277.16M
Anavex Life Sciences Corp. focuses on developing treatments for neurological disorders, similar to NTI's focus on neurology and brain health.
Axon Enterprise
AXON
Mkt Cap48.8B
Axon Neuroscience SE engages in the development of therapeutics for neurodegenerative diseases, directly competing in NTI's market space.
Biogen
BIIB
Mkt Cap32.28B
Biogen Inc. specializes in therapies for neurological diseases, aligning closely with NTI's focus on neurotherapeutic products.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals, Inc. develops RNA-targeted therapies, including treatments for neurological diseases, competing with NTI's research and products.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company has a strong portfolio in neurodegenerative treatments, making it a direct competitor in the neurological sector.
Novartis
NVS
Mkt Cap292.35B
Novartis AG offers several products for neurological conditions, competing in the same therapeutic area as NTI.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a diversified portfolio that includes treatments for neurological disorders, positioning it as a competitor to NTI.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG develops various neurology-focused therapies, directly competing with NTI's product range.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals Incorporated works on advanced treatments for several diseases, including neurological disorders, competing with NTI.

About

Neurotech International Limited (NTI.AX), along with its subsidiaries, is an Australian firm dedicated to the research, development, and manufacture of innovative medical devices and solutions. The company's primary focus lies in advancing and commercializing its Mente platform, a technological system designed to monitor and facilitate home-based therapies. This includes its Mente Autism product, specifically aimed at the diagnosis and treatment of autism spectrum disorder. Additionally, Neurotech actively undertakes various medical research projects and engineers new technological instruments. The company was established in 2016 and maintains its headquarters in Nedlands, Australia.
Show more...
CEO
Anthony Filippis
Employees
18
Country
Australia
ISIN
AU000000NTI9

Listings

AU
AU
NTI.AU

0 Comments

Share your thoughts

FAQ

What is Neurotech International Limited stock price today?▼
The current price of NTI.AU is A$0.01 AUD — it has increased by +3.85% in the past 24 hours. Watch Neurotech International Limited stock price performance more closely on the chart.
What is Neurotech International Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Australia Exchange exchange Neurotech International Limited stocks are traded under the ticker NTI.AU.
Is Neurotech International Limited stock price growing?▼
NTI.AU stock has risen by +3.85% compared to the previous week, the month change is a -10% fall, over the last year Neurotech International Limited has showed a -3.57% decrease.
What is Neurotech International Limited market cap?▼
Today Neurotech International Limited has the market capitalization of 17.79M
When is the next Neurotech International Limited earnings date?▼
Neurotech International Limited is going to release the next earnings report on March 02, 2027.
What is Neurotech International Limited revenue for the last year?▼
Neurotech International Limited revenue for the last year amounts to 0 AUD.
What is Neurotech International Limited net income for the last year?▼
NTI.AU net income for the last year is -10.6M AUD.
How many employees does Neurotech International Limited have?▼
As of September 05, 2026, the company has 18 employees.
In which sector is Neurotech International Limited located?▼
Neurotech International Limited operates in the Health & Wellness sector.
When did Neurotech International Limited complete a stock split?▼
Neurotech International Limited has not had any recent stock splits.
Where is Neurotech International Limited headquartered?▼
Neurotech International Limited is headquartered in Melbourne, Australia.